Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 20/20 | 0.81 |
| ▸ | GABRG2 | P18507 | 20/20 | 0.81 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.81 |
| ▸ | GABRA3 | P34903 | 17/20 | 0.81 |
| ▸ | GABRA5 | P31644 | 14/20 | 0.69 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659859 | 0.93 | GABRA1 (0.81) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2657954 | 0.93 | GABRA1 (0.70) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL30139355 | 0.93 | GABRA1 (0.70) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2658463 | 0.92 | GABRA1 (0.68) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2658839 | 0.90 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL5775431 | 0.90 | GABRA1 (0.67) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2657810 | 0.88 | GABRA1 (0.68) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659569 | 0.88 | GABRA1 (0.66) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659472 | 0.88 | GABRA1 (0.79) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659844 | 0.87 | GABRA1 (0.75) | GABRA1GABRG2GABRB3GABRA3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414636-A1 | USE OF GABAA MODULATORS FOR TREATMENT OF RESPIRATORY CONDITIONS | SAGE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| US-20220117916-A1 | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose | SAFERX PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | US | claimed |
| EP-1511747-B1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-04-12 | — | — | EP | claimed |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2005-07-28 | — | — | US | claimed |
| EP-1511747-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-03-09 | — | — | EP | claimed |
| WO-2003099816-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-12-04 | — | — | WO | claimed |
| EP-4665755-A1 | POLYPEPTIDES BINDING TO THE NEONATAL FC RECEPTOR | Ablynx N.V. (BE) | 2025-12-24 | — | — | EP | disclosed |
| US-12433898-B2 | Use of GABAA receptor modulators for treatment of itch | UNIVERSITAT ZURICH (CH) | 2025-10-07 | — | — | US | disclosed |
| US-20250287407-A1 | Orchestrating Migration of Edge Computing Resources | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2025-09-11 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250268912-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | UNIVERSITAT ZURICH (CH) | 2025-08-28 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| EP-3468545-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | President and Fellows of Harvard College (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3407886-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | Universität Zürich (CH) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017214442-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017129801-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | Universität Zürich (CH) | 2017-08-03 | — | — | WO | disclosed |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| EP-1511747-B1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414636-A1 | USE OF GABAA MODULATORS FOR TREATMENT OF RESPIRATORY CONDITIONS | GABRB2, GABRB1, GABRA2 | GABRA1 5/4885GABRG2 16/4885GABRB3 4/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | GABRA1 2370/4885GABRG2 2243/4885GABRB3 2951/4885 |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA5 | GABRA1 5/4885GABRG2 15/4885GABRB3 6/4885 |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | GABRB2, GABRA4, GABRB1 | GABRA1 5/4885GABRG2 12/4885GABRB3 8/4885 |
| US-20250268912-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | GABRB2, GABRB3, GABRB1 | GABRA1 11/4885GABRG2 8/4885GABRB3 2/4885 |
| US-12433898-B2 | Use of GABAA receptor modulators for treatment of itch | GABRB2, GABRB3, GABRB1 | GABRA1 11/4885GABRG2 8/4885GABRB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.